Attached files

file filename
10-K - MONOPAR THERAPEUTICS INC. - Monopar Therapeuticsmnpr_form10k.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Monopar Therapeuticsexhibit_32-1.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit_31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit_31-1.htm
EX-14 - CODE OF BUSINESS CONDUCT AND ETHICS - Monopar Therapeuticsexhibit_14.htm
EX-11 - STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS - Monopar Therapeuticsexhibit_11.htm
EX-10.16 - CANCER RESEARCH UK LETTER DATED MARCH 21, 2018 - Monopar Therapeuticsexhibit_10-16.htm
EX-10.14 - PRX CONSULTING AGREEMENT 2018 - Monopar Therapeuticsexhibit_10-14.htm
EX-10.13 - ANDERSON EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-13.htm
EX-10.12 - PRX CONSULTING AGREEMENT 2017 - Monopar Therapeuticsexhibit_10-12.htm
EX-10.11 - MAZAR EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-11.htm
EX-10.10 - MAZAR CONSULTING AGREEMENT - Monopar Therapeuticsexhibit_10-10.htm
EX-10.9 - TSUCHIMOTO EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-9.htm
EX-10.8 - TSUCHIMOTO CONSULTING AGREEMENT - Monopar Therapeuticsexhibit_10-8.htm
EX-10.7 - ROBINSON EMPLOYMENT AGREEMENT AMENDED AND RESTATED - Monopar Therapeuticsexhibit_10-7.htm
EX-10.6 - ROBINSON EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-6.htm
EX-10.5 - MONOPAR THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN - Monopar Therapeuticsexhibit_10-5.htm
EX-10.4 - TACTICGEM CONTRIBUTION AGREEMENT - Monopar Therapeuticsexhibit_10-4.htm
EX-10.3 - ONXEO OPTION AND LICENSE AGREEMENT - Monopar Therapeuticsexhibit_10-3.htm
EX-10.2 - XOMA LICENSE AGREEMENT - Monopar Therapeuticsexhibit_10-2.htm
EX-10.1 - CANCER RESEARCH UK CTOA - Monopar Therapeuticsexhibit_10-1.htm
EX-3.2 - AMENDED AND RESTATE BYLAWS - Monopar Therapeuticsexhibit_3-2.htm
EX-3.1 - SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Monopar Therapeuticsexhibit_3-1.htm
 
 
 
 
 
First Amendment to Employment Agreement between Kim R. Tsuchimoto (“Executive”) and Monopar Therapeutics Inc. (“Company”) dated November 1, 2017. The following amendments are made effective March 1, 2018. All other unrevised sections remain in full force.
 
 
2.1 Position and Duties, Executive will devote Executive’s best efforts and 50% of Executive’s business time and attention (except for vacation periods and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies or as otherwise set forth in this Agreement) to the business of the Company.
 
 
 
3.1 Base Salary, Executive shall receive for services to be rendered hereunder an annual base salary of $137,500 representing 50% of full-time.
 
3.3 Standard Company Benefits, Executive shall be entitled to all benefits offered by the Company so long as Executive devotes 50% or more time to the business of the Company. In lieu of benefits, Executive shall be reimbursed up to $1,800 per month for out-of-pocket expenses for medical, dental and vision benefits until such time the Company has benefit plans in place. Based upon 50% service, Executive shall be entitled each year to two (2) weeks leave for vacation at full pay, provided, that the maximum amount Executive may have accrued at any point in time is two (2) weeks (meaning that once Executive has accrued two (2) weeks, Executive will not accrue any additional vacation time until she takes vacation and falls below the two (2) week accrual cap).
 
 
Pursuant to section 6.1(a) Other Activities, Exhibit A
 
25% of full-time employment with no benefits at Mercaptor Discoveries Inc. as Chief Financial Officer, Secretary, Treasurer and Co-Founder
 
Minimal time, as needed, at DNAcheckup as a volunteer Chief Financial Officer, Secretary and Treasurer
 
 
Requested by:
 
/s/ Kim R. Tsuchimoto
 
February 26, 2018
Kim R. Tsuchimoto                                                                            
Date
 
 
 
Approved by:
 
/s/ Chandler D. Robinson
                                                                          
March 1, 2018
 
Chandler D. Robinson                                                                            
Date
Monopar Therapeutics Inc.
 
Co-Founder, Chief Executive Officer and Director